The Global Drug Discovery Services Market was valued at USD 19.2 billion in 2025 and is estimated to grow at a CAGR of 13.5% to reach USD 67.3 billion by 2035.
The market is experiencing expansion as pharmaceutical and biotechnology companies increasingly rely on external research partners to improve discovery efficiency, reduce development timelines, and optimize research investments. The growing complexity of modern drug development, increasing adoption of advanced computational approaches, and rising demand for innovative therapies are accelerating the use of specialized drug discovery service providers. A major factor shaping future growth is the transition toward strategic outsourcing, where companies are forming long-term collaborations with contract research organizations (CROs) to access advanced capabilities and flexible research models. The rising presence of biologics in development pipelines and the growing application of artificial intelligence across discovery workflows are further enhancing market opportunities. AI-based platforms are improving efficiency in areas such as target identification, molecule screening, and candidate assessment, helping researchers make faster and more informed decisions. Continued pharmaceutical R&D investment, with global spending exceeding USD 250 billion annually, is supporting demand for outsourced discovery solutions as companies seek greater speed, scalability, and cost control throughout the innovation process.
The target selection segment held a 10.3% share in 2025, highlighting its importance as an early-stage activity that influences the overall success of drug development programs. This segment focuses on identifying and evaluating biological targets that can potentially deliver therapeutic benefits for specific medical conditions. Advancements in computational biology, data analytics, and AI-enabled research platforms have expanded the ability of scientists to explore new therapeutic opportunities and improve target validation processes.
The pharmaceutical and biotechnology segment held a 68.8% share in 2025. The strong position of this segment is supported by the increasing dependence of drug developers on outsourced research services to enhance internal capabilities, accelerate discovery timelines, and manage operational costs. CRO partnerships allow companies to access specialized expertise and advanced technologies while maintaining flexibility throughout research programs.
North America Drug Discovery Services Market held a 45.56% share in 2025. The region’s leadership is supported by the strong presence of pharmaceutical and biotechnology companies, advanced research infrastructure, significant investment in life sciences innovation, and a regulatory framework that supports advanced drug discovery and development activities.
Major players operating in the global drug discovery services market are WuXi AppTec Co., Ltd.; Charles River Laboratories International, Inc.; Evotec SE; Pharmaron Beijing Co., Ltd.; Thermo Fisher Scientific Inc. (PPD); Eurofins Scientific SE; Labcorp Drug Development; Syngene International Limited; Curia Global, Inc.; BioDuro-Sundia; Sai Life Sciences Limited; Selvita S.A.; Aragen Life Sciences Ltd.; Aurigene Pharmaceutical Services Ltd.; and Sygnature Discovery Ltd. Key strategies adopted by companies in the drug discovery services market include expanding service portfolios, investing in AI-driven research platforms, strengthening technology capabilities, and building strategic partnerships with pharmaceutical and biotechnology firms. Leading providers are focusing on integrated discovery solutions that cover multiple stages of research to improve customer retention and create long-term collaborations. Companies are also increasing investments in automation, advanced analytics, and specialized scientific expertise to enhance efficiency and deliver faster outcomes.
This product will be delivered within 2-4 business days.
The market is experiencing expansion as pharmaceutical and biotechnology companies increasingly rely on external research partners to improve discovery efficiency, reduce development timelines, and optimize research investments. The growing complexity of modern drug development, increasing adoption of advanced computational approaches, and rising demand for innovative therapies are accelerating the use of specialized drug discovery service providers. A major factor shaping future growth is the transition toward strategic outsourcing, where companies are forming long-term collaborations with contract research organizations (CROs) to access advanced capabilities and flexible research models. The rising presence of biologics in development pipelines and the growing application of artificial intelligence across discovery workflows are further enhancing market opportunities. AI-based platforms are improving efficiency in areas such as target identification, molecule screening, and candidate assessment, helping researchers make faster and more informed decisions. Continued pharmaceutical R&D investment, with global spending exceeding USD 250 billion annually, is supporting demand for outsourced discovery solutions as companies seek greater speed, scalability, and cost control throughout the innovation process.
The target selection segment held a 10.3% share in 2025, highlighting its importance as an early-stage activity that influences the overall success of drug development programs. This segment focuses on identifying and evaluating biological targets that can potentially deliver therapeutic benefits for specific medical conditions. Advancements in computational biology, data analytics, and AI-enabled research platforms have expanded the ability of scientists to explore new therapeutic opportunities and improve target validation processes.
The pharmaceutical and biotechnology segment held a 68.8% share in 2025. The strong position of this segment is supported by the increasing dependence of drug developers on outsourced research services to enhance internal capabilities, accelerate discovery timelines, and manage operational costs. CRO partnerships allow companies to access specialized expertise and advanced technologies while maintaining flexibility throughout research programs.
North America Drug Discovery Services Market held a 45.56% share in 2025. The region’s leadership is supported by the strong presence of pharmaceutical and biotechnology companies, advanced research infrastructure, significant investment in life sciences innovation, and a regulatory framework that supports advanced drug discovery and development activities.
Major players operating in the global drug discovery services market are WuXi AppTec Co., Ltd.; Charles River Laboratories International, Inc.; Evotec SE; Pharmaron Beijing Co., Ltd.; Thermo Fisher Scientific Inc. (PPD); Eurofins Scientific SE; Labcorp Drug Development; Syngene International Limited; Curia Global, Inc.; BioDuro-Sundia; Sai Life Sciences Limited; Selvita S.A.; Aragen Life Sciences Ltd.; Aurigene Pharmaceutical Services Ltd.; and Sygnature Discovery Ltd. Key strategies adopted by companies in the drug discovery services market include expanding service portfolios, investing in AI-driven research platforms, strengthening technology capabilities, and building strategic partnerships with pharmaceutical and biotechnology firms. Leading providers are focusing on integrated discovery solutions that cover multiple stages of research to improve customer retention and create long-term collaborations. Companies are also increasing investments in automation, advanced analytics, and specialized scientific expertise to enhance efficiency and deliver faster outcomes.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Methodology & Scope
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2025
Chapter 5 Market Estimates and Forecast, by Process, 2022-2035 ($ Mn)
Chapter 6 Market Estimates and Forecast, by Type, 2022-2035 ($ Mn)
Chapter 7 Market Estimates and Forecast, by Drug Type, 2022-2035 ($ Mn)
Chapter 8 Market Estimates and Forecast, by Therapeutic Area, 2022-2035 ($ Mn)
Chapter 9 Market Estimates and Forecast, by End Use, 2022-2035 ($ Mn)
Chapter 10 Market Estimates and Forecast, by Region, 2022-2035 ($ Mn)
Chapter 11 Company Profiles
Companies Mentioned
- Charles River Laboratories International, Inc.
- WuXi AppTec Co., Ltd.
- Pharmaron Beijing Co., Ltd.
- Labcorp Drug Development
- Evotec SE
- Thermo Fisher Scientific Inc.
- Eurofins Scientific SE
- Syngene International Limited
- Curia Global, Inc.
- Sai Life Sciences Limited
- Aragen Life Sciences Ltd.
- Sygnature Discovery Ltd.
- BioDuro-Sundia
- Aurigene Pharmaceutical Services Ltd.
- Selvita S.A.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | June 2026 |
| Forecast Period | 2025 - 2035 |
| Estimated Market Value ( USD | $ 19.2 Billion |
| Forecasted Market Value ( USD | $ 67.3 Billion |
| Compound Annual Growth Rate | 13.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
